2019 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Ensuring Treatment for Children with Orphan Diseases: Ending Exemptions from the Pediatric Research Equity Act (PREA)
August 27, 2019 – This policy brief was developed by TAG and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and it details how children with TB are affected by the pediatric research exemption for orphan drugs. The brief also proposes…
Statement on U.S. FDA Report Highlighting Gaps in Pediatric Research
Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.
TB Activist Toolkits
TAG's TB Activist Toolkits provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and understanding of the latest innovations, evidence, and guidance around TB and TB/HIV. These toolkits cover important base knowledge on TB and TB/HIV, as well…
Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.
Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid
Treatment Action Group welcomes simpler, shorter treatment options for people with some forms of drug-resistant tuberculosis, while urging additional research and equitable access.
The Tuberculosis Vaccines Pipeline
June 2013 Where are we going, where have we been? By Mike Frick Since the 2012 Pipeline Report, results from phase II trials and advances in preclinical development have brought the pipeline for new TB vaccines into sharper focus, even…
The Tuberculosis Treatment Pipeline
June 2013 Better than Ever Is Not Good Enough By Erica Lessem NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction In December 2012, tuberculosis (TB) treatment reached a historic…
The Tuberculosis Diagnostics Pipeline
June 2013 By Colleen Daniels Currently, smear microscopy and mycobacterial culture are the most widely used diagnostic tests, but microscopy, though relatively fast, is too inaccurate—missing over half of cases1—while culture is accurate but slow, taking from two to eight…
The Tuberculosis Vaccines Pipeline
July 2014 Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses have yielded to new investigative directions, and unresolved questions…